来源：央视网 近日天气多变，呼吸道疾病高发。很多人认为吃药时最好也用热水，对肠胃和身体更友好。然而从科学 服药角度来看并非如此。"热水送药并不总是对的。"广州市红十字会医院药学部主任、广州市临床用药 质控中心主任张述耀在接受媒体采访时表示，"用热水（尤其是超过40℃的水）送服某些药物，会破坏 药效，甚至增加风险。临床中，我们就曾遇到过因用热水送服肠溶胶囊导致胃部不适、药物无效的案 例。"原来，服药用水也有讲究，用什么样的水送服、水量多少、水温高低等，都可能影响药效。吃胶 囊药不要用热水送服专家介绍，胶囊是临床常见的药物剂型，约占医生开具处方的20%，但它有个弱点 ——怕热水。根据胶囊"囊材"的不同，可分为明胶胶囊和植物胶囊。其中，明胶是应用最多的成囊材 料，这是一种蛋白质制品，成分中85%~90%为蛋白质，不溶于冷水，但容易在温水和热水中溶解。有 试验发现，胶囊在50℃的水里浸泡10秒钟，就会变软、变黏稠。哪怕胶囊外壳只是化了一部分，也会变 得像粘了一块泡泡糖一样，拉丝、发黏。胶囊长时间和食管接触、在错误位置溶解、药物提前释放，可 能会带来以下健康风险。1、损伤食管若胶囊粘在食管，可能在食管局部形成高渗环境， ...

转自：央视网 近日天气多变，呼吸道疾病多发。很多人认为吃药时最好也用热水，对肠胃和身体更友好。然而从科学 服药角度来看并非如此。 "热水送药并不总是对的。"广州市红十字会医院药学部主任、广州市临床用药质控中心主任张述耀在接 受媒体采访时表示，"用热水（尤其是超过40℃的水）送服某些药物，会破坏药效，甚至增加风险。临 床中，我们就曾遇到过因用热水送服肠溶胶囊导致胃部不适、药物无效的案例。" 生病服药的时候，应该喝凉水还是热水？能否用茶水或饮料代替？其实，服药用水也有讲究，用什么样 的水送服、水量多少、水温高低等，都可能影响药效。 吃胶囊药不要用热水送服 专家介绍，胶囊是临床常见的药物剂型，但它有个弱点——怕热水。 根据胶囊"囊材"的不同，可分为明胶胶囊和植物胶囊。其中，明胶是应用最多的成囊材料，这是一种蛋 白质制品，成分中85%~90%为蛋白质，不溶于冷水，但容易在温水和热水中溶解。 有试验发现，胶囊在50℃的水里浸泡10秒钟，就会变软、变黏稠。哪怕胶囊外壳只是化了一部分，也会 变得像粘了一块泡泡糖一样，拉丝、发黏。 胶囊长时间和食管接触、在错误位置溶解、药物提前释放，可能会带来以下健康风险。 损伤食管 若胶囊 ...

民间素有冬至时节进补的习惯。冬季食疗进补包含温阳与滋阴两方面。平素畏寒怕冷、手脚发凉的人适 合温阳，可多食羊肉、牛肉等。常有口干咽燥、手足心热的人则需要滋阴，宜选择木耳、银耳等食 物。"食补和个人年龄、体质、居住环境都有关系，最好先咨询医生。"高峰说。 本报讯（记者柴嵘）冬至节气，标志着将进入一年中最寒冷的阶段。中国中医科学院望京医院医生高峰 提醒，要注意防寒保暖，外出及时增添衣物，饮食上合理搭配，营养均衡。喝酒、吃辣祛寒御冷不可 取。 "人们常说冬天喝点酒、吃点辣能祛寒御冷，这并不正确。"高峰说，饮酒后身体散热更快，反而容易受 寒感冒。许多药物也会与酒产生不良反应，如常用的头孢类抗菌药、解热镇痛药等，用药前后一周内都 应避免饮酒，否则可能出现心悸、呕吐等严重不适，甚至危及生命。儿童、孕妇及哺乳期女性等人群也 不宜饮酒。此外，辛辣食物容易耗伤津液，可能加重口干、便秘，慢性胃炎等消化系统疾病患者尤其需 注意。 ...

本文转自【羊城晚报】； 抗组胺药（典型如感冒药、抗过敏药）、解热镇痛药、镇静催眠药、降压降糖药、镇咳药等药物，在服 用后会引起嗜睡、头晕、视力模糊、反应迟钝等副作用，严重影响驾驶安全。 广大驾驶人如有身体不适，在看医生或服药前，一定要向医生讲清楚自己有驾车需求，仔细阅读药品说 明书上的"不良反应""禁忌"等文字，若标注"服药后不得驾驶机、车、船、从事高空作业、机械作业及 操作精密仪器"，切记在服药后不要开车，或待几小时后副作用消退再开车！ 防范疲劳驾驶，广大驾驶人日常应保持规律作息、睡眠充分，确保有足够的精力体力应对每日的驾驶任 务。同时尽量避免午后、夜间尤其是凌晨两点至五点等易困时段驾车。 有长途驾车需求的，应在出发前规划好途中的休息节奏，并在途中根据体力、精力消耗情况，结合"逢 三进一"原则，在尚未感到疲惫、困倦时就到服务区休息调整，切勿抱着"还不困可以继续开车""困了再 找地方休息"的心理上路！ 来源 | 公安部交通管理局、央视新闻 刘某告诉交警，称自己感冒发烧，早上刚吃了药，行至事发地点时突然困意发作，"前一秒还是清醒 的，一下子就昏了"，从而引发事故。 交警提醒 据公安部交通管理局12月20日发布视 ...

来源：公安部交通管理局 交警提醒 抗组胺药（典型如感冒药、抗过敏药）、解热镇痛药、镇静催眠药、降压降糖药、镇咳药等药物，在服 用后会引起嗜睡、头晕、视力模糊、反应迟钝等副作用，严重影响驾驶安全。 2025年12月11日，福银高速江西抚州段。上午09:30分许，刘某驾车行驶时，车辆忽然失控向右偏离车 道，撞上路边标志牌及护栏。 刘某告诉交警，称自己感冒发烧，早上刚吃了药，行至事发地点时突然困意发作，"前一秒还是清醒 的，一下子就昏了"，从而引发事故。 广大驾驶人如有身体不适，在看医生或服药前，一定要向医生讲清楚自己有驾车需求，仔细阅读药品说 明书上的"不良反应""禁忌"等文字，若标注"服药后不得驾驶机、车、船、从事高空作业、机械作业及 操作精密仪器"，切记在服药后不要开车，或待几小时后副作用消退再开车！ ...

Market Overview - The market experienced a high and then a pullback, with the three major indices slightly down. The pharmaceutical sector continued its strong performance, with stocks like Qizheng Zangyao and Asia-Pacific Pharmaceutical hitting the daily limit. AI application stocks remained active, with companies like Qidi Design and Zhengzhong Design also reaching the limit. The photovoltaic sector saw a collective rebound, with stocks such as Jiejia Weichuang and Shuangliang Energy hitting the limit. Overall, more stocks rose than fell, with over 3,300 stocks in the Shanghai and Shenzhen markets showing gains, and today's trading volume was 1.62 trillion, a decrease of over 340 billion from the previous day [1]. Sector Highlights Pharmaceuticals - The pharmaceutical sector continued to surge, with Qizheng Zangyao achieving three consecutive limits, and Asia-Pacific Pharmaceutical and Fuyuan Pharmaceutical also hitting the limit. Notable stock performances include: - Qizheng Zangyao: Latest price 34.69, up 9.99%, market cap 18.389 billion [5] - Asia-Pacific Pharmaceutical: Latest price 7.40, up 9.96%, market cap 5.518 billion [6] - Fuyuan Pharmaceutical: Latest price 26.54, up 9.99%, market cap 12.739 billion [6] - Analysts believe the innovative drug sector's prosperity is sustainable, driven by policy support and increasing global competitiveness. The recovery of overseas orders and performance in the innovative drug supply chain is also noted, with expectations for a rebound in demand by 2025 [4][6]. Artificial Intelligence - The AI application sector saw significant gains, with stocks like Huanqiu Printing and Zhengzhong Design hitting the limit. Notable performances include: - Huanqiu Printing: Latest price 10.16, up 9.96%, market cap 3.252 billion [10] - Zhengzhong Design: Latest price 11.66, up 10.00%, market cap 3.301 billion [10] - Qidi Design: Latest price 16.08, up 20.00%, market cap 2.695 billion [10] - The recent strong debut of Figma on the NYSE, closing at $115.5 with a 250% increase, highlights the potential for AI-driven design tools to disrupt traditional markets [8][11]. Photovoltaics - The photovoltaic sector showed renewed strength, with stocks like Wenkai Co. and Jiejia Weichuang hitting the limit. Key stock performances include: - Wenkai Co.: Latest price 4.84, up 10.00%, market cap 2.145 billion [13] - Jiejia Weichuang: Latest price 66.19, up 20.00%, market cap 19.006 billion [12] - Jiejia Weichuang's recent earnings forecast indicates a net profit of 1.7 to 1.96 billion, representing a year-on-year growth of 38.65% to 59.85% [12]. - The Ministry of Industry and Information Technology's recent notice on energy conservation in the polysilicon industry is expected to accelerate supply-side reforms in the photovoltaic sector [12][14].

Industry Overview - The Chinese active pharmaceutical ingredients (API) industry plays a crucial role in the pharmaceutical sector, being the largest producer and exporter globally, particularly in antibiotics, vitamins, and analgesics [8][31] - APIs are essential for drug production, requiring processing into formulations for clinical use, and are widely applied in pharmaceuticals, cosmetics, and other fields [8][10] Market Development - The global API market is steadily growing, projected to reach $226.1 billion in 2024, with China's chemical API revenue expected to be ¥578.3 billion, accounting for 35.5% of the global market [3][39] - The biopharmaceutical API market in China was approximately ¥120 billion in 2023, anticipated to grow to ¥180 billion by 2025, reflecting a compound annual growth rate of about 12% [3][39] - In terms of capacity, China's API production peaked at 3.48 million tons in 2017 but declined due to environmental regulations, with a gradual recovery starting in 2020 [3][40] Enterprise Landscape - By 2024, three companies are expected to exceed ¥10 billion in revenue, with New and Better being the leader, while the majority of enterprises are concentrated in Jiangsu and Shandong provinces [4][39] - The market is characterized by a low concentration, with small and medium-sized enterprises dominating, and direct sales being the primary sales model [4][39] Challenges Faced - The industry faces several challenges, including insufficient investment in R&D, high market entry barriers, lack of industry chain collaboration, intensified competition, and increased compliance costs [4][39] - Domestic regulatory issues include a dual-track system and inadequate transport adaptability, which complicate operations [4][39] Future Trends and Opportunities - The growth in pharmaceutical demand, advancements in biotechnology, and supportive policies present significant opportunities for the industry [4][39] - Key trends include the expiration of patents leading to market expansion, environmental regulations driving industry consolidation, integration of APIs and formulations, and the development of Contract Development and Manufacturing Organizations (CDMO) [4][39] - The industry is encouraged to embrace green practices, increase innovation investments, and enhance industry collaboration to improve competitiveness [4][39]

Core Viewpoint - The Jingmen Chemical Circular Industry Park is advancing its "oil-to-special" project, marking a new phase in the optimization and upgrading of the petrochemical industry, which is crucial for regional economic development [1] Group 1: Industry Development - The petrochemical industry is a pillar of the Jingmen Chemical Circular Industry Park, which has successfully attracted 28 downstream enterprises, creating a complete industrial ecosystem from basic raw materials to high-end new materials [2] - The park has implemented a "one enterprise, one policy" approach to optimize land use, reviving six inefficient enterprises and freeing up hundreds of acres for new projects [2] - The park is focusing on technological innovation and supporting enterprises in applying for provincial-level technical transformation projects to upgrade production processes [2] Group 2: Industrial Chain Collaboration - The park is enhancing industrial chain collaboration by attracting Fortune 500 and specialized projects, effectively connecting upstream and downstream enterprises within the carbon one industrial chain [3] - The lithium battery materials industry chain is thriving, with a complete lifecycle resource recycling model established, expected to generate a total output value of 20 billion yuan upon full production [3] - The park has achieved a virtuous cycle of "large projects driving the gathering of supporting enterprises and the development of industrial clusters" [3] Group 3: Quality and Precision in Development - The park emphasizes high-quality development by providing tailored solutions for enterprises facing labor shortages and financing difficulties, fostering collaboration among enterprises [4] - Significant investments are being made in key industries, such as a 1.5 billion yuan expansion of a photoinitiator project, which is expected to add 3.5 billion yuan in output value [4] Group 4: Niche Market Focus - The park adopts a "small but refined" approach, particularly in the waterproof materials industry, where it has attracted leading companies to form a specialized industrial chain expected to exceed 2 billion yuan in total output value [5] Group 5: Talent Development - The park prioritizes talent development by establishing a chemical safety skills training base and forming a talent alliance to integrate resources from universities and leading enterprises [6] - The collaboration with Wuhan University of Engineering aims to create a seamless connection between talent training and industry needs, enhancing the innovation vitality of the biopharmaceutical industry chain [6] - The biopharmaceutical sector has expanded its product matrix to cover 324 varieties across six categories, becoming a key driver of regional economic growth [6]

证券代码：600200 证券简称：江苏吴中 公告编号：临 2025-029 江苏吴中医药发展股份有限公司 关于 2025 年 1-3 月主要经营数据的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）主营业务 2025 年 1-3 月主要经营数据情况公告如下： 1、2025 年 1-3 月，公司医美生科业务累计实现主营业务收入 11,302.25 万元，较上年同期增长 11,175.09 万元，增长 8,781.59%，医美生科业务主营业 务毛利 9,257.49 万元，较上年同期增长 9,186.40 万元，增长 12,922.63%。 2025 年 1-3 月，公司医药业务累计实现主营业务收入 19,753.26 万元（其 中医药工业 13,972.06 万元，医药商业 5,781.21 万元），较上年同期减少 21,844.15 万元，减少 52.51%，医药业务主营业务毛利 10,473.57 万元，较上年 同期减少 3,547.84 万元，减少 25.30%。 治疗领域 ...